Current long-acting muscarinic antagonists for the treatment of asthma.
Administration, Inhalation
Adrenal Cortex Hormones
/ therapeutic use
Adrenergic beta-2 Receptor Agonists
/ therapeutic use
Asthma
/ drug therapy
Bronchodilator Agents
/ therapeutic use
Humans
Muscarinic Antagonists
/ therapeutic use
Pulmonary Disease, Chronic Obstructive
/ drug therapy
Tiotropium Bromide
/ therapeutic use
LAMA
Long-acting muscarinic antagonist
asthma
glycopyrronium bromide
tiotropium bromide
triple therapy
umeclidinium bromide
Journal
Expert opinion on pharmacotherapy
ISSN: 1744-7666
Titre abrégé: Expert Opin Pharmacother
Pays: England
ID NLM: 100897346
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
6
7
2021
medline:
15
12
2021
entrez:
5
7
2021
Statut:
ppublish
Résumé
The role of long-acting muscarinic antagonists (LAMAs) is well established in uncontrolled asthma, but not in milder stages. This review examines the main randomized controlled trials (RCTs) that have investigated LAMAs administered as monotherapy or in combination to asthmatic patients, according to the different phenotypes. It offers an overview of the role of LAMAs or their fixed dose combinations (FDCs) in the treatment across all the different stages of asthma. Tiotropium is now widely recognized as treatment for moderate to severe uncontrolled asthma (step 4-5) in adults and children. The most recent new evidence is: a) in adults, three different LAMA/long-acting β
Identifiants
pubmed: 34219573
doi: 10.1080/14656566.2021.1952182
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Bronchodilator Agents
0
Muscarinic Antagonists
0
Tiotropium Bromide
XX112XZP0J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM